Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

The field of Alzheimer's disease (AD) research eagerly awaits the results of a large number of Phase III clinical trials that are underway to investigate the effectiveness of anti-amyloid-β (Aβ) immunotherapy for AD. In this case report, we review the pertinent clinical history, examine the neuropathology, and characterize the Aβ profile of an AD patient who received bapineuzumab immunotherapy. The patient received four bapineuzumab infusions over a 39 week period. During the course of this treatment, there was no remarkable change in cognitive impairment as determined by MMSE scores. Forty-eight days after the fourth bapineuzumab infusion was given, MRI revealed that the patient had developed lacunar infarcts and possible vasogenic edema, probably related to immunotherapy, but a subsequent MRI scan 38 days later demonstrated resolution of vasogenic edema. The patient expired due to acute congestive heart failure complicated by progressive AD and cerebrovascular accident 378 days after the first bapineuzumab infusion and 107 days after the end of therapy. Neuropathological and biochemical analysis did not produce evidence of lasting plaque regression or clearance of Aβ due to immunotherapy. The Aβ species profile of this case was compared with non-immunized AD cases and non-demented controls and found to be similar to non-immunized AD cases. SELDI-TOF mass spectrometric analysis revealed the presence of full-length Aβ₁₋₄₂ and truncated Aβ peptides demonstrating species with and without bapineuzumab specific epitopes. These results suggest that, in this particular case, bapineuzumab immunotherapy neither resulted in detectable clearance of amyloid plaques nor prevented further cognitive impairment.

[1]  M. Sabbagh,et al.  The biochemical aftermath of anti-amyloid immunotherapy , 2010, Molecular Neurodegeneration.

[2]  C. Holmes,et al.  Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis , 2010, Acta Neuropathologica.

[3]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[4]  David A Wolk,et al.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease , 2010, Proceedings of the National Academy of Sciences.

[5]  K. Jellinger.  Con: Can neuropathology really confirm the exact diagnosis? , 2010, Alzheimer's Research & Therapy.

[6]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[7]  T. Comery,et al.  Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease , 2009, The Journal of Biological Chemistry.

[8]  J. Becker,et al.  In vivo amyloid deposition and neuropathological findings after humanized amyloid β-specific monoclonal antibodies therapy in a patient with Alzheimer's disease , 2009, Alzheimer's & Dementia.

[9]  B. Ghetti,et al.  Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations , 2008, Molecular Neurodegeneration.

[10]  R. Barbour,et al.  Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice , 2008, The Journal of Neuroscience.

[11]  T. Hortobágyi,et al.  Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia , 2008, Dementia and Geriatric Cognitive Disorders.

[12]  M. Pangalos,et al.  Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse , 2008, Neurodegenerative Diseases.

[13]  D. Connor,et al.  The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007 , 2007, Cell and Tissue Banking.

[14]  I. Ferrer,et al.  Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis , 2006 .

[15]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[16]  S. Paul,et al.  Altered APP Processing in PDAPP (Val717 → Phe) Transgenic Mice Yields Extended-Length Aβ Peptides. , 2005 .

[17]  B. Ghetti,et al.  Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. , 2005, Biochemistry.

[18]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[19]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[20]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[21]  Xiantao Wang,et al.  Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. , 2002, Brain : a journal of neurology.

[22]  Y. Ihara,et al.  Effect of Apolipoprotein E Allele ε4 on the Initial Phase of Amyloid β-Protein Accumulation in the Human Brain , 2000 .

[23]  P. Mehta,et al.  Traumatic Brain Injury Elevates the Alzheimer's Amyloid Peptide Aβ42 in Human CSF: A Possible Role for Nerve Cell Injury , 2000, Annals of the New York Academy of Sciences.

[24]  A. Roher,et al.  The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer’s Disease* , 1998, The Journal of Biological Chemistry.

[25]  M. Weinand,et al.  Amyloid-β Induces Chemokine Secretion and Monocyte Migration across a Human Blood-Brain Barrier Model , 1998, Molecular medicine.

[26]  M. Emmerling,et al.  Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. , 1997, Biochemical and biophysical research communications.

[27]  S. Mirra.  The CERAD Neuropathology Protocol and Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease: A Commentary , 1997, Neurobiology of Aging.

[28]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[29]  M. Tabaton,et al.  Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.

[30]  J. Rogers,et al.  Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. , 1997, The American journal of pathology.

[31]  A. Roher,et al.  Specific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia , 1996, The Journal of Neuroscience.

[32]  R N Kalaria,et al.  Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. , 1996, The American journal of pathology.

[33]  M. Ball,et al.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.

[34]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M J Ball,et al.  Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. , 1993, The Journal of biological chemistry.

[36]  Amos D. Korczyn,et al.  Vascular dementia , 1993, Journal of the Neurological Sciences.

[37]  Anders Wallin,et al.  Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. , 2005, Clinical chemistry.

[38]  S. Paul,et al.  Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides. , 2005, Biochemistry.

[39]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[40]  B. Ghetti,et al.  The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. , 2004, The Journal of biological chemistry.

[41]  M. Staufenbiel,et al.  APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. , 2002, Biochemistry.

[42]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  Y. Ihara,et al.  Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. , 2000, The American journal of pathology.

[44]  R. Motter,et al.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Shoji,et al.  Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. , 1995, Biochemical and biophysical research communications.